Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What Happened in the Stock Market Today
On a day the indexes closed with small losses, shares of Ignyta soared on news it was being bought by Roche, and Nike fell after reporting earnings.
Why Ignyta, Inc. Stock Is Soaring Today
Roche takes out U.S. cancer drug specialist Ignyta Inc. for $1.7 billion.
10 Frightening Lung-Cancer Statistics and 3 Top Companies Looking to Do Something About It
Cancer immunotherapies and targeted therapies offer renewed hope to lung-cancer patients.